Previous 10 | Next 10 |
Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern Time NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharm...
AzurRX Biopharma (NASDAQ: AZRX ): Q2 GAAP EPS of -$0.25 misses by $0.03 . More news on: AzurRx BioPharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported financial results for...
The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' ( PTI -1.6% ) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous ...
BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price ...
American Electric Technologies (NASDAQ: AETI ) -39% after stockholders approved share exchange transaction with Stabilis Energy. More news on: American Electric Technologies, Inc, Senseonics Holdings, Inc., Netflix, Inc., Stocks on the move, Read more ...
BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1...
Gainers: Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...
Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) is up 12% after hours on light volume in response to the launch of a Phase 2 clinical trial evaluating MS1819-SD, combined with standard porcine enzyme replacement therapy (PERT), in cystic fibrosis patients with severe ex...
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will have a management R&D update c...
News, Short Squeeze, Breakout and More Instantly...
AzurRx BioPharma Inc. Company Name:
AZRX Stock Symbol:
NASDAQ Market:
AzurRx BioPharma Inc. Website:
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (G...
Why Investors Are Watching These 3 Penny Stocks Right Now There are plenty of ways to find the best penny stocks to buy right now. And, one method that many penny stocks investors use is looking at what top investors are buying alongside other metrics. While this can be a good strat...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...